This content is from: Portfolio Investing in a Cure for Cancer The recently launched Loncar Cancer Immunotherapy ETF provides investors with a vehicle to bet on promising new immunotherapy treatments for cancer. By Kaitlin Ugolik June 07, 2016
In-network benefits Unlike other big drugmakers facing do-or-die pressure to merge, Switzerland's Roche has found a third way: Invest in a web of research partners and diversify into diagnostic equipment. August 07, 2005
